By inhibiting the important oncogenic pathways STAT3, AKT, and ERK, silybin therapy of breast cancer cells resistant to doxorubicin/paclitaxel sensitized cells to chemotherapeutic drugs [358]. Here, AKT1 is linked to breast carcinoma.